Clinical study on treatment of Omicron infection of Novel Coronavirus variant Strain with qingjin Huashi Granules

Shenzhen the 3rd People's Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) Age from 12 to 70, regardless of gender. Those who meet the diagnostic criteria of mild or common type of clinical pneumonia; (2) No heat or low heat (T<38.5°C); (3) Novel coronavirus positive, and the virus sequencing result is Omicron strain; (4) Consent to sign a written informed consent letter before the study begins (for subjects without behavioral capacity, if the researcher thinks it is in their own interests for them to participate in the study, the informed consent should be signed by their legal guardian and explained in the original medical records and other relevant documents).

•(1) Patients with severe non-infectious pulmonary underlying diseases, including pulmonary tumor, pulmonary edema, atelectasis, pulmonary embolism, pulmonary eosinophilic infiltration and pulmonary vasculitis; (2) Severe liver and kidney dysfunction: 1) ALT and AST more than 10 times the upper limit of normal value, 2) serum creatinine more than 1.5 times the upper limit of normal value, 3) total bilirubin more than 2 times the upper limit of normal value; (3) patients with biliary obstruction; (4) Pregnant women (positive urine or serum pregnancy test) or lactating women; (5) Subjects considered unsuitable for inclusion in this study by other researchers, or any conditions that may increase subjects' risk or interfere with the clinical trial as considered by the investigator.

发起方

Shenzhen the 3rd People's Hospital